NMLSF (Restart Life Sciences) ROCE % : 0.00% (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Restart Life Sciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Restart Life Sciences's annualized ROCE % for the quarter that ended in Sep. 2024 was 0.00%.

Restart Life Sciences ROCE % Historical Data

The historical data trend for Restart Life Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Restart Life Sciences ROCE % Chart

Restart Life Sciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-68.03

-18.30

-41.19

-188.10

-733.16

Restart Life Sciences Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

Restart Life Sciences ROCE % Calculation

Restart Life Sciences's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-1.426	/	( ( (0.688 - 0.33)	+	(0.219 - 0.188) )	/ 2 )
	=	-1.426	/	( (0.358	+	0.031)	/ 2 )
	=	-1.426	/	0.1945
	=	-733.16 %

Restart Life Sciences's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-0.364	/	( ( (0.019 - 0.782)	+	(0.196 - 0.629) )	/ 2 )
	=	-0.364	/	( ( -0.763	+	-0.433 )	/ 2 )
	=	-0.364	/	-0.598
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Restart Life Sciences (OTCPK:NMLSF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Restart Life Sciences ROCE % Related Terms

Thank you for viewing the detailed overview of Restart Life Sciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Restart Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Restart Life Sciences Corp (OTCPK:NMLSF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

HN3:Germany HN3:Germany HEAL.X:Canada

Address

700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6

Website

https://www.novamentis.ca

Restart Life Sciences Corp is a Canadian life sciences company dedicated to addressing today's health challenges with wellness solutions. It is focus is on creating health foods that address the needs of this community. Its Flagship developments includes Autism Spectrum, Health-Related Foods, Psilocybin Clinical Trial for Fragile X Syndrome, Orphan Drug Designation (FDA and EMA).